Alex Gillis

Post-doc at @SingMolSci and @UNSWRNA, UNSW | Cell biology, molecular pharmacology |

[Alex Gillis @acftbl]

We're excited to share this work! Have had a lot of fun trying to tackle this problem & some surprising results along the way.

[Scott Berry @scottbscience]

What happens when you suddenly remove half of an essential enzyme from cells? 🤔

We watched in real-time as cells deploy multiple backup strategies to buffer against changes in RNA Pol II abundance.

Our lab's new preprint 👇

https://t.co/GMUYJnieG9

[Alex Gillis @acftbl]

Pretty happy to share this work on RNA polymerase II!

We had a lot of fun studying this seemingly quite fundamental component of the system controlling Pol II levels & transcription. Amazing to get to work closely with Ana's group on this, combining imaging with genomics.

[Scott Berry @scottbscience]

📢 New paper from the lab!

In a fantastic new collaboration with @ana_tufegdzic lab, we characterise a major Pol II homeostasis pathway in human cells. Congratulations Roberta @caciopporobi, Alex @acftbl, Ivan @IvanShlamovitz, and Andrew.

https://t.co/B4xOaHDR7V

[Alex Gillis @acftbl]

@KLabGPCR @NatureNeuro Yes, I noted that! I ask as there is a fair bit of literature on mixed strain backgrounds altering phenotypes - you might be interested in this classic review on exactly this problem.

https://t.co/of74HbsUzc

[Alex Gillis @acftbl]

@samuel_b_phd Near the bottom and going backwards. All of us working within Aus know that firsthand.

[Alex Gillis @acftbl]

@samuel_b_phd (Germany of course being yet another country investing a far greater % GDP into research than Australia!)

[Alex Gillis @acftbl]

@samuel_b_phd I have to say Sam, BioNTech might disagree about which country that mRNA vaccine was created in…

[Alex Gillis @acftbl]

fascinating and ambitious work. @tobinatthelab Do you have any further data on the apparent selectivity over M2/3? It would be good to see HTL9936 tested in an additional assay to pERK, tested for antagonism, or some competition affinity measurements.

[Andrew Tobin @tobinatthelab]

Potential treatment for memory loss in AD - amazing to work with colleagues @UofGlasgow and @soseiheptaresco - production made slight error in title - being corrected - but the message is clear @UofGIMCSB @UofGMVLS @UofGARC @UoG_TransPharm
https://t.co/kTTIwCdOhy

[Alex Gillis @acftbl]

This is only becoming more important as more of us are pushed into casual or precarious employment. Big companies like USYD will exploit you if you let them.

[Alex Gillis @acftbl]

Reminder to join your union wherever ever you work. There’s a lot that is crook about modern unis but pressure from organised labour protects workers. I am one (hopefully of many) beneficiary of this campaign against historical underpayment.

[NTEU New South Wales @NTEUNSW]

NTEU members knew USyd had a chronic underpayments issue. Without the activism of NTEU members, USyd would have been able to sweep this under the rug. Now workers will be paid what they're owed. https://t.co/oIJT5lqhik to help your fellow members stop wage theft! #highered

[Alex Gillis @acftbl]

The precise role of MOR phosphorylation, and βarrestin recruitment, in this is an interesting outstanding question. More critically, it is unclear to what extent tolerance and withdrawal signs relate to 'addictive liability' of certain ligands.

[Alex Gillis @acftbl]

With the publication of this interesting paper (and our associated commentary), I thought I would go through some elements of the broader discussion to highlight some work we were unable to cite.

https://t.co/VLhB54rGbO

[Alex Gillis @acftbl]

As we discuss in our commentary, there is clearly a complex and yet to be understood series of mechanisms leading to both opioid tolerance and somatic withdrawal.

https://t.co/ayi5iyw6At